Since the company was founded in 2011, Symbiosis has grown from a Scottish startup into an internationally recognised sterile manufacturer of injectable drug products, supporting both clinical development and commercial supply across a wide range of therapeutic areas.
Over the past 14 years, the company has delivered complex injectable products spanning monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), viral vectors, small molecules, and advanced therapy medicinal products (ATMPs).
Symbiosis played a pivotal role in the clinical development of the Oxford University/AstraZeneca COVID-19 vaccine, manufacturing nearly one million doses at its Stirling facility to support clinical trials and enable accelerated regulatory approval in the UK.
Today, Symbiosis supports clients through phase I, II and III clinical trials and commercial-scale manufacturing across the globe.
“Reaching our 1,000th batch is a proud moment for everyone at Symbiosis,” said Colin MacKay, CEO of Symbiosis. “As global demand for sterile drug products rises, it reflects our commitment to manufacturing excellence and our shared purpose of helping deliver life-saving medicines to patients faster.”
Symbiosis has maintained a consistent track record of successful GMP inspections from regulatory agencies including the US FDA and UK MHRA since the company began, underscoring its reputation for regulatory compliance and manufacturing excellence.
“2025 has been a landmark year for Symbiosis; winning the King’s Award for Enterprise in International Trade to launching our new automated commercial-scale manufacturing facility in Stirling,” Colin added. “Symbiosis will continue to build upon this momentum, helping more clients deliver innovative medicines to patients around the world.”
